[EFFECT] Regulus Therapeutics Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

Rhea-AI Filing Summary

07/02/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	July 1, 2025

Accession Number:

0001104659-25-062437

Submission Type:

POS AM

CIK:	0001505512
Company Name:	Regulus Therapeutics Inc.
File Number:	333-203292

Source: View Original Filing on SEC EDGAR

Regulus Therapeu

NASDAQ:RGLS

RGLS Rankings

#6774 Ranked by Market Cap

N/A Ranked by Dividends

RGLS Latest News

May 8, 2025

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

Apr 30, 2025

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

Apr 2, 2025

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Mar 27, 2025

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 13, 2025

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

RGLS Latest SEC Filings

Jul 2, 2025

[EFFECT] Regulus Therapeutics Inc. SEC Filing

Jul 2, 2025

[EFFECT] Regulus Therapeutics Inc. SEC Filing

Jul 2, 2025

[EFFECT] Regulus Therapeutics Inc. SEC Filing

Jul 2, 2025

[EFFECT] Regulus Therapeutics Inc. SEC Filing

Jul 2, 2025

[EFFECT] Regulus Therapeutics Inc. SEC Filing

RGLS Stock Data

Market Cap 545.56M

Float 67.29M

Insiders Ownership 2.18%

Institutions Ownership 82.48%

Short Percent 3.42%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City SAN DIEGO